Aprea Therapeutics, Inc. (APRE) Insider Trading Activity

NASDAQ$1.06
Market Cap
$6.47M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
368 of 827
Rank in Industry
212 of 469

APRE Insider Trading Activity

APRE Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$10,110
1
100
Sells
$0
0
0

Related Transactions

Gilad OrenPresident/CEO
1
$10,110
0
$0
$10,110

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Insider Activity of Aprea Therapeutics, Inc.

Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $10,110 and sold $0 worth of Aprea Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $111,657 and sold $1.41M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Gilad Oren (President/CEO) — $10,110.

The last purchase of 5,500 shares for transaction amount of $10,110 was made by Gilad Oren (President/CEO) on 2025‑04‑03.

List of Insider Buy and Sell Transactions, Aprea Therapeutics, Inc.

2025-04-03PurchaseGilad OrenPresident/CEO
5,500
0.1023%
$1.84
$10,110
-11.67%
2024-10-23PurchaseGilad OrenPresident/CEO
500
0.0086%
$3.92
$1,958
-53.33%
2024-10-18SaleDuey Marcdirector
6,462
0.1238%
$4.58
$29,583
-58.18%
2024-10-16PurchaseDuey Marcdirector
30,000
0.8303%
$4.39
$131,700
-47.29%
2024-10-15PurchaseGilad OrenPresident/CEO
250
0.0046%
$2.90
$725
-39.18%
2024-10-14PurchaseGilad OrenPresident/CEO
1,000
0.0163%
$2.59
$2,590
-27.34%
2024-10-14PurchaseDuey Marcdirector
190
0.0031%
$2.58
$490
-27.34%
2024-10-11PurchaseSeizinger Bernd R.director
10,000
0.169%
$2.68
$26,800
-28.08%
2024-10-11PurchaseHamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
50
0.0008%
$2.46
$123
-28.08%
2024-10-10PurchaseGilad OrenPresident/CEO
150
0.0024%
$2.54
$381
-26.18%
2024-10-10PurchaseHamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
450
0.0074%
$2.61
$1,175
-26.18%
2024-03-13PurchaseGilad OrenPresident, CEO
2,000
0.0683%
$7.29
$14,580
-31.44%
2024-03-13PurchaseSeizinger Bernd R.director
6,860
0.2342%
$7.29
$50,009
-31.44%
2024-03-13PurchaseHamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
1,010
0.0345%
$7.29
$7,363
-31.44%
2024-03-13PurchaseHENNEMAN JOHN B IIIdirector
6,860
0.2342%
$7.29
$50,009
-31.44%
2023-06-07PurchaseSeizinger Bernd R.director
6,029
0.1917%
$3.68
$22,192
+18.87%
2023-06-06PurchaseSeizinger Bernd R.director
4,068
0.1208%
$3.63
$14,764
+11.20%
2020-12-28SaleRedmile Group, LLC10 percent owner
500,000
2.4014%
$5.58
$2.79M
-11.73%
2020-10-05Sale5AM Ventures IV, L.P.Former 10% holder
175,000
0.7844%
$25.30
$4.43M
-80.91%
2020-07-07SaleKDev Investments AB10 percent owner
241,703
1.1593%
$34.55
$8.35M
-79.65%
Total: 39
*Gray background shows transactions not older than one year

Insider Historical Profitability

9.05%
Gilad OrenPresident/CEO
345620
5.6631%
$366,357.2060
<0.0001%
Christenson Johandirector
2366104
38.7696%
$2.51M10
+53.58%
HealthCap VII, L.P.10 percent owner
2366104
38.7696%
$2.51M10
+53.58%
KDev Investments AB10 percent owner
1992586
32.6494%
$2.11M02
Redmile Group, LLC10 percent owner
1768718
28.9812%
$1.87M11
+53.58%
Versant Vantage I, L.P.10 percent owner
333333
5.4618%
$353,332.9810
+53.58%
Versant V Luxco S.a r.l.10 percent owner
333333
5.4618%
$353,332.9810
+53.58%
Duey Marcdirector
233651
3.8285%
$247,670.0621
<0.0001%
5AM Ventures IV, L.P.Former 10% holder
138497
2.2693%
$146,806.8214
+53.58%
ROCKLAGE SCOTT MFormer 10% holder
75965
1.2447%
$80,522.9003
Seizinger Bernd R.director
44730
0.7329%
$47,413.8040
<0.0001%
Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
19368
0.3174%
$20,530.0830
<0.0001%
HENNEMAN JOHN B IIIdirector
8139
0.1334%
$8,627.3420
+11.07%
Magni Guidodirector
6500
0.1065%
$6,890.0010
+53.58%
SCHADE CHRISTIAN SPresident & CEO
5000
0.0819%
$5,300.0010
+53.58%
Coiante Scott MSVP, Chief Financial Officer
2500
0.041%
$2,650.0010
+53.58%
Korbel Gregory AlanVP of Business Dev't
500
0.0082%
$530.0010
+53.58%
Attar Eyal C.SVP, Chief Medical Officer
200
0.0033%
$212.0010
+53.58%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$22,360,243
40
22.92%
$4.97M
$13,664,154
40
-70.35%
$7.07M
$1,029,337
36
-28.38%
$6.62M
$1,138,733
28
-4.94%
$4.39M
Aprea Therapeutics, Inc.
(APRE)
$29,635,355
27
9.05%
$6.47M
$547,862
19
-29.82%
$7.89M
$1,556,551
15
-25.43%
$7.4M
$20,715,938
10
-42.51%
$6.17M
$120,379
10
-24.48%
$7.45M
$90,087
9
20.06%
$6.67M
$8,971,546
8
6.18%
$5.61M
$84,058
7
-61.66%
$7.11M
$159,974
7
-18.60%
$7.61M
$76,299
4
11.60%
$6.47M
$149,778
4
-45.16%
$4.38M
$4,423
2
3.27%
$6.04M
$19,863
1
144.27%
$4.63M
$739,010
1
3.33%
$4.56M
$75,000
1
-30.67%
$5.09M

APRE Institutional Investors: Active Positions

Increased Positions7+26.92%17,932+0.99%
Decreased Positions8-30.77%214,589-11.82%
New Positions2New12,269New
Sold Out Positions2Sold Out14,966Sold Out
Total Postitions25-3.85%2M-10.83%

APRE Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Aigh Capital Management Llc$680.008.99%539,30000%2025-09-30
Sphera Funds Management Ltd.$340.004.5%270,00000%2025-09-30
Nantahala Capital Management, Llc$259.003.43%205,76000%2025-09-30
Vanguard Group Inc$199.002.64%158,238-15,604-8.98%2025-09-30
Dafna Capital Management Llc$173.002.29%137,17400%2025-09-30
Sio Capital Management, Llc$141.001.87%112,223-167,146-59.83%2025-09-30
Morgan Stanley$83.001.1%65,808+2,477+3.91%2025-09-30
Geode Capital Management, Llc$56.000.74%44,616+1,479+3.43%2025-09-30
Bnp Paribas Financial Markets$22.000.29%17,132+1,700+11.02%2025-09-30
Lpl Financial Llc$20.000.27%16,052-1,000-5.86%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.